10.05.2013 NEXUS AG  DE0005220909

DGAP-Adhoc: NEXUS AG: Strong increase in Result and Sales in the first Quarter 2013


 
NEXUS AG / Key word(s): Quarter Results 10.05.2013 08:20 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Villingen-Schwenningen, 10 May 2013 NEXUS AG, specialized in medical software, was able to increase sales by 20% from KEUR 13,855 in Q1-2012 to KEUR 16,604 in Q1-2013. The operating result after taxes increased by 20.5% to KEUR 1,702 (Q1-2012: KEUR 1,413). The sales increase in the Healthcare Software Division was 12.9% and amounted to KEUR 14,509 following KEUR 12,853 in the previous year. Sales in the Healthcare Service Division increased by approx. 109.1% in the first quarter 2013 to KEUR 2,095 (Q1-2012: KEUR 1,002). The sales of ASS.TEC GmbH and E&L medical systems GmbH consolidated for the first time contributed to part of the sale increase (12.9%). The result before taxes improved by 18.1% to KEUR 1,662 (Q1-2012: KEUR 1,407) in comparison to the previous year, and the result after taxes increased to KEUR 1,702 following KEUR 1,413 in the previous year (+20.5%). The EBITDA increased by approx. 17.1% to KEUR 3,240 (Q1-2012: KEUR 2,767) during the reporting period. The cash flow from on-going business transactions was at a high level at KEUR 4,547, but was lower than in the previous year (Q1-2012: KEUR 6,353). The share of international business in sales volume was 42.9% or KEUR 7,125 in the first quarter (Q1-2012: KEUR 6,952). With approx. EUR 69.7 million equity capital, NEXUS AG has a healthy balance sheet and sufficient capital to finance further growth. Cash reserves increased by approx. KEUR 2,941 to EUR 25.9 million compared to the end of the business year (31 December 2012: EUR 23.1 million). NEXUS - the eHealth specialist - develops and sells modular software solutions internationally for healthcare systems in the areas of Clinical Information Systems› (CIS), ‹Diagnostic Information Systems› (DIS) and ‹IT Services›. Comprehensive solutions for hospitals and psychiatric institutions are designed and supported within NEXUS / CIS. The solutions of NEXUS / DIS cover special ward and specialist areas for radiology, pathology as well as for gynecology / obstetrics and intensive care medicine. NEXUS bets on modern, modular software architecture in all product areas, which enables flexible and step-by-step introduction of NEXUS systems. More than 578 staff members in the NEXUS Group develop software solutions for the healthcare sector, with which approximately 158,600 users in 23 countries work. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: Further Information: NEXUS AG Mr. Simon Holzer Tel.: +49 (0) 77 21/84 82 0 Fax: +49 (0) 77 21/84 82 311 [email protected] www.nexus-ag.de 10.05.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: NEXUS AG Auf der Steig 6 78052 Villingen-Schwenningen Germany Phone: +49 (0)7721 8482-0 Fax: +49 (0)7721 8482-888 E-mail: [email protected] Internet: www.nexus-ag.de ISIN: DE0005220909 WKN: 522090 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 107,05 119,08 136,47 147,65 162,94 188,18 195,00
EBITDA1,2 21,02 23,72 26,71 33,95 36,64 40,77 44,00
EBITDA-Marge3 19,64 19,92 19,57 22,99 22,49 21,67 22,56
EBIT1,4 10,93 13,32 15,18 17,44 19,92 24,11 25,50
EBIT-Marge5 10,21 11,19 11,12 11,81 12,23 12,81 13,08
Jahresüberschuss1 8,61 10,16 11,00 12,12 15,09 17,46 19,00
Netto-Marge6 8,04 8,53 8,06 8,21 9,26 9,28 9,74
Cashflow1,7 16,54 21,68 20,24 24,62 30,95 31,37 33,00
Ergebnis je Aktie8 0,52 0,62 0,69 0,69 0,96 1,09 1,20
Dividende8 0,15 0,16 0,17 0,18 0,19 0,20 0,22
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
Nexus
WKN Kurs in € Einschätzung Börsenwert in Mio. €
522090 50,000 Kaufen 790,73
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
35,46 33,99 1,05 68,68
KBV KCV KUV EV/EBITDA
5,83 25,21 4,20 18,75
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,19 0,20 0,40 29.04.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
17.05.2022 16.08.2022 08.11.2022 08.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,34% -18,45% -30,17% -20,38%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu NEXUS AG  ISIN: DE0005220909 können Sie bei DGAP abrufen


Software , 522090 , NXU , XETR:NXU